Frequency Therapeutics (Frequency Therapeutics) GF Value : $2.58 (As of May. 11, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Frequency Therapeutics GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-11), Frequency Therapeutics's share price is $0.2996. Frequency Therapeutics's GF Value is $2.58. Therefore, Frequency Therapeutics's Price-to-GF-Value for today is 0.12.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Frequency Therapeutics is Data Out of Date, Use Caution.

Frequency Therapeutics (NAS:FREQ) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Frequency Therapeutics's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	0.2996	/	2.58
	=	0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequency Therapeutics GF Value Related Terms

Thank you for viewing the detailed overview of Frequency Therapeutics's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Frequency Therapeutics (Frequency Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Frequency Therapeutics Inc (NAS:FREQ) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 Hayden Avenue, Suite 300, Lexington, MA, USA, 02421

Website

https://www.frequencytx.com

Frequency Therapeutics Inc is a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by degenerative diseases. Its Progenitor Cell Activation approach uses combinations of molecules to activate progenitor cells within the body to create functional tissue. Its product candidate FX-322 is being developed for treating sensorineural hearing loss.

Executives

Richard J. Mitrano	officer: VP Finance & Operations	C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
David L. Lucchino	director, officer: President and CEO	C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Christopher R. Loose	officer: Chief Scientific Officer	C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Quentin Mccubbin	officer: Chief Manufacturing Officer	C/O FREQUENCY THERAPEUTICS, INC., 10 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Wendy S Arnold	officer: Chief People Officer	19 PRESIDENTIAL WAY, SUITE 203, WOBURN MA 01801
Carl Lebel	officer: Chief Development Officer	23256 MARIPOSA DE ORO, MALIBU CA 90265
Peter P. Pfreundschuh	officer: Chief Financial Officer	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Michael Bookman	officer: General Counsel and Secretary	C/O FREQUENCY THERAPEUTICS, INC., 10 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Joel S Marcus	director, 10 percent owner	C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Cynthia L Feldmann	director	17 WINTHROP ROAD, WAYLAND MA 01778
Marc A Cohen	director	1000 WILSON BLVD. #1800, ARLINGTON VA 22209
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p.	10 percent owner, other: Possible Member of 10% Group	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Robert Langer	director	98 MONTVALE RD, NEWTON MA 02459
Alexandria Venture Investments, Llc	10 percent owner	26 NORTH EUCLID AVENUE, PASADENA CA 91101